These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1198 related articles for article (PubMed ID: 11245477)

  • 21. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
    Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
    Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
    Suzuki T; Suda N; Ohyama K
    J Bone Miner Metab; 2004; 22(3):185-91. PubMed ID: 15108059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.
    Chikatsu N; Takeuchi Y; Tamura Y; Fukumoto S; Yano K; Tsuda E; Ogata E; Fujita T
    Biochem Biophys Res Commun; 2000 Jan; 267(2):632-7. PubMed ID: 10631114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
    Ono K; Akatsu T; Murakami T; Kitamura R; Yamamoto M; Shinomiya N; Rokutanda M; Sasaki T; Amizuka N; Ozawa H; Nagata N; Kugai N
    J Bone Miner Res; 2002 May; 17(5):774-81. PubMed ID: 12009007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
    Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
    Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
    Lai FP; Cole-Sinclair M; Cheng WJ; Quinn JM; Gillespie MT; Sentry JW; Schneider HG
    Br J Haematol; 2004 Jul; 126(2):192-201. PubMed ID: 15238139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts.
    Tada T; Jimi E; Okamoto M; Ozeki S; Okabe K
    Int J Cancer; 2005 Aug; 116(2):253-62. PubMed ID: 15800904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts.
    Boabaid F; Berry JE; Koh AJ; Somerman MJ; McCcauley LK
    J Periodontol; 2004 Sep; 75(9):1247-54. PubMed ID: 15515341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
    Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
    J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
    Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
    Ishizuka K; Hirukawa K; Nakamura H; Togari A
    Neurosci Lett; 2005 Apr; 379(1):47-51. PubMed ID: 15814197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.